Acupuncture, Moxibustion & Meridian Research Group, Korea Institute of Oriental Medicine, Daejeon, Korea.
Trials. 2013 Jul 18;14:225. doi: 10.1186/1745-6215-14-225.
The purpose of this study is to conduct a basic analysis of the effectiveness and safety of electroacupuncture in the treatment of painful diabetic neuropathy (PDN) as compared to placebo and usual care and to evaluate the feasibility of large-scale clinical research.
METHODS/DESIGN: This study is a protocol for a three-armed, randomized, patient-assessor-blinded (to the type of treatment), controlled pilot trial. Forty-five participants with a ≥ six month history of PDN and a mean weekly pain score of ≥ 4 on the 11-point Pain Intensity Numerical Rating Scale (PI-NRS) will be assigned to the electroacupuncture group (n = 15), sham group (n = 15) or usual care group (n = 15). The participants assigned to the electroacupuncture group will receive electroacupuncture (remaining for 30 minutes with a mixed current of 2 Hz/120 Hz and 80% of the bearable intensity) at 12 standard acupuncture points (bilateral ST36, GB39, SP9, SP6, LR3 and GB41) twice per week for eight weeks (a total of 16 sessions) as well as the usual care. The participants in the sham group will receive sham electroacupuncture (no electrical current will be passed to the needle, but the light will be seen, and the sound of the pulse generator will be heard by the participants) at non-acupuncture points as well as the usual care. The participants in the usual care group will not receive electroacupuncture treatment during the study period and will receive only the usual care. The follow-up will be in the 5th, 9th and 17th weeks after random allocation. The PI-NRS score assessed at the ninth week will be the primary outcome measurement used in this study. The Short-Form McGill Pain Questionnaire (SF-MPQ), a sleep disturbance score (11-point Likert scale), the Short-Form 36v2 Health Survey (SF-36), the Beck Depression Inventory (BDI) and the Patient Global Impression of Change (PGIC) will be used as outcome variables to evaluate the effectiveness of the acupuncture. Safety will be assessed at every visit.
The result of this trial will provide a basis for the effectiveness and safety of electroacupuncture for PDN.
Clinical Research information Service. Unique identifier: KCT0000466.
本研究旨在对电针治疗痛性糖尿病周围神经病变(PDN)的有效性和安全性进行基础分析,与安慰剂和常规护理进行比较,并评估其开展大规模临床研究的可行性。
方法/设计:这是一项三臂、随机、患者评估者设盲(对治疗类型)、对照性的初步试验方案。45 名 PDN 病史≥6 个月、11 点疼痛强度数字评分量表(PI-NRS)平均每周疼痛评分≥4 的参与者将被分配到电针组(n=15)、假电针组(n=15)或常规护理组(n=15)。电针组的参与者将接受电针治疗(混合电流 2 Hz/120 Hz,强度为 80%可耐受强度,持续 30 分钟),每周两次,共 8 周(共 16 次),同时接受常规护理。假电针组的参与者将在非穴位处接受假电针治疗(不会有电流通过针,但参与者会看到光,听到脉冲发生器的声音),同时接受常规护理。常规护理组的参与者在研究期间不会接受电针治疗,仅接受常规护理。随访将在随机分组后的第 5、9 和 17 周进行。本研究的主要疗效评估指标为第 9 周的 PI-NRS 评分。简短麦吉尔疼痛问卷(SF-MPQ)、睡眠障碍评分(11 分 Likert 量表)、简短健康调查量表 36 版 2(SF-36)、贝克抑郁量表(BDI)和患者总体变化印象(PGIC)将作为评估针灸疗效的结局变量。每次就诊时都会评估安全性。
本试验的结果将为电针治疗 PDN 的有效性和安全性提供依据。
临床研究信息服务。独特标识符:KCT0000466。